Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Auteurs : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Année : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009

New generation of breast cancer clinical trials implementing molecular profiling.

Auteurs : Zardavas D, Piccart-Gebhart M
Année : 2016
Journal : Cancer Biol Med
Volume : 13
Pages : 226-35

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Auteurs : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Année : 2016
Journal : N Engl J Med
Volume : 375(8)
Pages : 717-29

Metastatic breast cancer: The Odyssey of personalization.

Auteurs : Sonnenblick A, Pondé N, Piccart-Gebhart M
Année : 2016
Journal : Mol oncol
Volume : 10(8)
Pages : 1147-59

Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

Auteurs : Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart-Gebhart M, Zardavas D, Nagele E, Bjelic-Radisic V, Cardoso F, Sprangers MA, Velikova G, Bottomley A
Année : 2016
Journal : Lancet Oncol
Volume : 17
Pages : e294-304

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Auteurs : Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart-Gebhart M, Sotiriou C, Litiere S, Pierga JY
Année : 2016
Journal : Eur J Cancer
Volume : 63
Pages : 97-104

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Auteurs : Deliens C, Deliens G, Filleul O, Pepersack T, Awada A, Piccart-Gebhart M, Praet JP, Dal Lago L
Année : 2016
Journal : J Geriatr Oncol
Volume : 7(6)
Pages : 463-70

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1519-25

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

Auteurs : Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart-Gebhart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P
Année : 2016
Journal : Lancet Oncol
Volume : 17
Pages : 811-21

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Auteurs : Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart-Gebhart M, Azim HA Jr
Année : 2016
Journal : J Natl Cancer Inst
Volume : 108

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Année : 2016
Journal : Eur J Cancer
Volume : 60
Pages : 117-124

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Auteurs : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Année : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pages : 1040-7

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

Auteurs : Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, Von Minckwitz G, Buyse M, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27(6)
Pages : 1029-34

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT0006

Auteurs : Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart-Gebhart M, Cameron D
Année : 2016
Journal : Eur J Cancer
Volume : 53
Pages : 144-54

Breast cancer in 2015: Academic research sheds light on issues that matter to patients.

Auteurs : Piccart-Gebhart M, Gingras I
Année : 2016
Journal : Nat Rev Clin Oncol
Volume : 13
Pages : 67-8

Reply to the letter to the editor 'The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice' by Hartmann and the letter 'Comment on ESMO Magnitude of Clinical Benefit Scale' by Muhonen et al.

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Année : 2016
Journal : Ann Oncol
Volume : 27
Pages : 203-5

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Auteurs : Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
Année : 2016
Journal : J Clin Oncol
Volume : 34(16)
Pages : 1872-81

The current use and attitudes towards tumor genome sequencing in breast cancer.

Auteurs : Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart-Gebhart M, Sotiriou C, Ignatiadis M, Azim HA Jr
Année : 2016
Journal : Sci Rep
Volume : 6
Pages : 22517

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Auteurs : Strasser-Weippl K, Horick N, Smith IE, O Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Année : 2016
Journal : Eur J Cancer
Volume : 56
Pages : 85-92

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Auteurs : Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M
Année : 2016
Journal : Lancet Oncol
Volume : 17(3)
Pages : 357-66